Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals Limited held its Annual General Meeting where the Chairman and CEO addressed shareholders. The company continues to expand its product approvals globally, with Illuccix® and Gozellix® receiving approvals from various international health agencies. This expansion strengthens Telix’s market position in the biopharmaceutical industry, potentially enhancing its operational capabilities and stakeholder value.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company that focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company is developing a portfolio of clinical and commercial stage products targeting significant unmet medical needs in oncology and rare diseases. Telix’s notable products include Illuccix®, a PSMA-PET imaging agent, and Scintimun®, an osteomyelitis imaging agent.
Average Trading Volume: 2,006,483
Technical Sentiment Signal: Buy
Current Market Cap: A$8.7B
For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.